LONDON – AstraZeneca PLC (AZN.LN) Wednesday said the European Commission approved its breast cancer treatment Faslodex for post-menopausal women after a Phase III trial showed it reduces the risk of disease progression by 20% compared with anastrozole, the current standard treatment.
Continue Reading Below
-Write to Rory Gallivan at email@example.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
July 26, 2017 12:15 ET (16:15 GMT)